Primary Progressive Multiple Sclerosis Under Anti-TNFα Treatment: A Case Report.
Multiple sclerosis
adalinumab
anti-TNFα
demyelinating disease
Journal
Journal of central nervous system disease
ISSN: 1179-5735
Titre abrégé: J Cent Nerv Syst Dis
Pays: United States
ID NLM: 101595026
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
06
2020
accepted:
24
10
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Antagonists of tumour necrosis factor α (TNFα) are a common therapeutic choice for autoimmune diseases. Although they are effective and relatively safe, an increasing number of immune-mediated adverse events have been reported. Among these, neurological adverse effectsm such as consisting of demyelinating events in the central and peripheral nervous system were described. Demyelination of the central nervous system is a rare complication after treatment with TNFα antagonists. Here, we report a case of multiple sclerosis under treatment with TNFα antagonists and discuss its etiopathogenesis. This 45-year-old female patient developed signs and symptoms suggestive of primary progressive multiple sclerosis during treatment with adalinumab for nodular cystic acne, and magnetic resonance imaging of the patient showed typical lesions of demyelinating disease.
Identifiants
pubmed: 33424233
doi: 10.1177/1179573520973820
pii: 10.1177_1179573520973820
pmc: PMC7755935
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179573520973820Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests:The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Ann Neurol. 1999 Jun;45(6):695-703
pubmed: 10360761
Medicine (Baltimore). 2007 Jul;86(4):242-251
pubmed: 17632266
Ther Adv Neurol Disord. 2020 Jan 2;13:1756286419895155
pubmed: 31921355
Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1181-95
pubmed: 17127203
Immunotherapy. 2010 Nov;2(6):817-33
pubmed: 21091114
Rheumatology (Oxford). 2010 Nov;49(11):2217-9
pubmed: 20837498
Semin Arthritis Rheum. 2011 Dec;41(3):524-33
pubmed: 22152489
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
J Neuroimmunol. 2011 May;234(1-2):1-6
pubmed: 21474190
Nat Rev Neurol. 2011 Mar;7(3):165-72
pubmed: 21263460
J Exp Med. 2001 Feb 19;193(4):427-34
pubmed: 11181695
Autoimmun Rev. 2014 Jan;13(1):54-8
pubmed: 24035809
J Neurol. 2006 May;253(5):668-9
pubmed: 16311894
Eur J Neurol. 2017 Jun;24(6):825-834
pubmed: 28544411
Nat Rev Rheumatol. 2016 Jan;12(1):49-62
pubmed: 26656660
J Rheumatol. 2006 May;33(5):1027-8
pubmed: 16541474
Neuroscience. 2015 Aug 27;302:2-22
pubmed: 26117714